Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Osama Abu-Shawer
Observed name:
Osama Abu Shawer
Institutions:
University Hospitals of Cleveland,
University Hospitals Cleveland Medical Center,
Case Western Reserve University
Observed institutions:
Cleveland Clinic,
University Hospitals of Cleveland,
University Hospitals Cleveland Medical Center,
Case Western Reserve University
ORCID:
0000-0003-3904-2673
Observed ORCID:
0000-0003-3904-2673
OpenAlex ID:
A5138454044
Maternal, obstetrical, and neonatal outcomes in celiac disease
2024
·
Khaled Alsabbagh Alchirazi
, Claire Jansson-Knodell
, et al.
·
Scandinavian Journal of Gastroenterology
·
6
Volatile versus intravenous anesthesia and postoperative neurocognition: A meta-analysis and trial-sequential analysis
2026
·
Jibran Ikram
, Aizaz Ali
, et al.
·
Journal of Clinical Anesthesia
·
3
General vs. non-general anesthesia for transcatheter aortic valve replacement: A real-world target trial emulation study
2026
·
Mahmoud S. Mohamed
, Osama Abu-Shawer
, et al.
·
Journal of Clinical Anesthesia
PDF
Supplementary Methods S1 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
·
Bridget Adcock
, Moaath K. Mustafa Ali
, et al.
Supplementary Table S3 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
·
Bridget Adcock
, Moaath K. Mustafa Ali
, et al.
Supplementary Methods S2 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
·
Bridget Adcock
, Moaath K. Mustafa Ali
, et al.
Supplementary Figure S2 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
·
Bridget Adcock
, Moaath K. Mustafa Ali
, et al.
Supplementary Table S7 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
·
Bridget Adcock
, Moaath K. Mustafa Ali
, et al.
Supplementary Table S11 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
·
Bridget Adcock
, Moaath K. Mustafa Ali
, et al.
Supplementary Figure S1 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
·
Bridget Adcock
, Moaath K. Mustafa Ali
, et al.
Supplementary Table S1 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
·
Bridget Adcock
, Moaath K. Mustafa Ali
, et al.
Supplementary Table S2 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
·
Bridget Adcock
, Moaath K. Mustafa Ali
, et al.
Supplementary Table S6 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
·
Bridget Adcock
, Moaath K. Mustafa Ali
, et al.
Supplementary Table S9 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
·
Bridget Adcock
, Moaath K. Mustafa Ali
, et al.
Supplementary Table S8 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
·
Bridget Adcock
, Moaath K. Mustafa Ali
, et al.
Supplementary Table S4 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
·
Bridget Adcock
, Moaath K. Mustafa Ali
, et al.
Supplementary Table S10 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
·
Bridget Adcock
, Moaath K. Mustafa Ali
, et al.
Supplementary Table S5 from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
·
Bridget Adcock
, Moaath K. Mustafa Ali
, et al.
Data from The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
2026
·
Bridget Adcock
, Moaath K. Mustafa Ali
, et al.
Show more works
View as search
Works count:
19
Citation count:
9
H-index:
2
I10-index:
Year
Topic
Type